Calculus Capital leads £6m round for Arecor

Albion Capital and Downing Ventures also took part in the round.

The company will use the fresh capital to accelerate the clinical development of its diabetes speciality pharma portfolio. Arecor plans to complete a series of first-in-man clinical trials for each of its three diabetic compounds and ultimately partner with specialist diabetes companies for late-stage clinical studies and global market access.

Previous funding
Arecor was awarded a grant worth £1m from UK public body Innovate UK in January 2018.

Company
Established in 2007 and based in Cambridge, Arecor specialises in developing proprietary formulations of generic insulin and glucagon drugs, which are used for the regulation of blood glucose in patients with diabetes.

People
Calculus Capital – Alexander Crawford (investment director).
Arecor – Sarah Howell (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Calculus Capital
• Albion Ventures
• United Kingdom
• Venture